Oncolytics Biotech receives favorable Final Advice Letter from the...


Oncolytics Biotech announces that the company has received a favorable Final Advice Letter from the European Medicines Agency . The Letter refers to the proposed use of pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative metastatic breast cancer patients in a pivotal phase 3 registration study and suggests that a single 400-patient study may be acceptable to form the basis for a marketing application in Europe.



from Biotech News